Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukemia patients, we identified 50 who had discontinued imatinib for at least six months; of these we analyzed 43. Molecular recurrence was detected in 19 patients, and a complete molecular response rate was estimated to be 47% following imatinib discontinuation. Based on multivariate regression analysis, imatinib dose intensity and prior interferon-α administration were independently predictive of molecular recurrence within 12 months. The depth of the molecular response should be a factor influencing long-term sustained complete molecular response after discontinuation of imatinib. Additionally, an immunological mechanism modified by interferon-α might control chronic myeloid leukemia stem cells.

Original languageEnglish
Pages (from-to)903-906
Number of pages4
JournalHaematologica
Volume97
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Leukemia, Myeloid, Chronic Phase
Myeloid Progenitor Cells
Recurrence
Imatinib Mesylate
Japan
Multivariate Analysis
Regression Analysis

Keywords

  • Chronic myeloid leukemia
  • Discontinuation
  • Imatinib
  • Molecular recurrence

ASJC Scopus subject areas

  • Hematology

Cite this

Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., ... Ohyashiki, K. (2012). Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 97(6), 903-906. https://doi.org/10.3324/haematol.2011.056853

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. / Takahashi, Naoto; Kyo, Taiichi; Maeda, Yasuhiro; Sugihara, Takashi; Usuki, Kensuke; Kawaguchi, Tatsuya; Usui, Noriko; Okamoto, Shinichiro; Ohe, Yokiko; Ohtake, Shigeki; Kitamura, Kunio; Yamamoto, Masahide; Teshima, Hirofumi; Motoji, Toshiko; Tamaki, Toshiharu; Sawada, Kenichi; Ohyashiki, Kazuma.

In: Haematologica, Vol. 97, No. 6, 01.06.2012, p. 903-906.

Research output: Contribution to journalArticle

Takahashi, N, Kyo, T, Maeda, Y, Sugihara, T, Usuki, K, Kawaguchi, T, Usui, N, Okamoto, S, Ohe, Y, Ohtake, S, Kitamura, K, Yamamoto, M, Teshima, H, Motoji, T, Tamaki, T, Sawada, K & Ohyashiki, K 2012, 'Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia', Haematologica, vol. 97, no. 6, pp. 903-906. https://doi.org/10.3324/haematol.2011.056853
Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012 Jun 1;97(6):903-906. https://doi.org/10.3324/haematol.2011.056853
Takahashi, Naoto ; Kyo, Taiichi ; Maeda, Yasuhiro ; Sugihara, Takashi ; Usuki, Kensuke ; Kawaguchi, Tatsuya ; Usui, Noriko ; Okamoto, Shinichiro ; Ohe, Yokiko ; Ohtake, Shigeki ; Kitamura, Kunio ; Yamamoto, Masahide ; Teshima, Hirofumi ; Motoji, Toshiko ; Tamaki, Toshiharu ; Sawada, Kenichi ; Ohyashiki, Kazuma. / Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. In: Haematologica. 2012 ; Vol. 97, No. 6. pp. 903-906.
@article{defde415ec6a43aaaa4299dab88e4af5,
title = "Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia",
abstract = "It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukemia patients, we identified 50 who had discontinued imatinib for at least six months; of these we analyzed 43. Molecular recurrence was detected in 19 patients, and a complete molecular response rate was estimated to be 47{\%} following imatinib discontinuation. Based on multivariate regression analysis, imatinib dose intensity and prior interferon-α administration were independently predictive of molecular recurrence within 12 months. The depth of the molecular response should be a factor influencing long-term sustained complete molecular response after discontinuation of imatinib. Additionally, an immunological mechanism modified by interferon-α might control chronic myeloid leukemia stem cells.",
keywords = "Chronic myeloid leukemia, Discontinuation, Imatinib, Molecular recurrence",
author = "Naoto Takahashi and Taiichi Kyo and Yasuhiro Maeda and Takashi Sugihara and Kensuke Usuki and Tatsuya Kawaguchi and Noriko Usui and Shinichiro Okamoto and Yokiko Ohe and Shigeki Ohtake and Kunio Kitamura and Masahide Yamamoto and Hirofumi Teshima and Toshiko Motoji and Toshiharu Tamaki and Kenichi Sawada and Kazuma Ohyashiki",
year = "2012",
month = "6",
day = "1",
doi = "10.3324/haematol.2011.056853",
language = "English",
volume = "97",
pages = "903--906",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "6",

}

TY - JOUR

T1 - Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

AU - Takahashi, Naoto

AU - Kyo, Taiichi

AU - Maeda, Yasuhiro

AU - Sugihara, Takashi

AU - Usuki, Kensuke

AU - Kawaguchi, Tatsuya

AU - Usui, Noriko

AU - Okamoto, Shinichiro

AU - Ohe, Yokiko

AU - Ohtake, Shigeki

AU - Kitamura, Kunio

AU - Yamamoto, Masahide

AU - Teshima, Hirofumi

AU - Motoji, Toshiko

AU - Tamaki, Toshiharu

AU - Sawada, Kenichi

AU - Ohyashiki, Kazuma

PY - 2012/6/1

Y1 - 2012/6/1

N2 - It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukemia patients, we identified 50 who had discontinued imatinib for at least six months; of these we analyzed 43. Molecular recurrence was detected in 19 patients, and a complete molecular response rate was estimated to be 47% following imatinib discontinuation. Based on multivariate regression analysis, imatinib dose intensity and prior interferon-α administration were independently predictive of molecular recurrence within 12 months. The depth of the molecular response should be a factor influencing long-term sustained complete molecular response after discontinuation of imatinib. Additionally, an immunological mechanism modified by interferon-α might control chronic myeloid leukemia stem cells.

AB - It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukemia patients, we identified 50 who had discontinued imatinib for at least six months; of these we analyzed 43. Molecular recurrence was detected in 19 patients, and a complete molecular response rate was estimated to be 47% following imatinib discontinuation. Based on multivariate regression analysis, imatinib dose intensity and prior interferon-α administration were independently predictive of molecular recurrence within 12 months. The depth of the molecular response should be a factor influencing long-term sustained complete molecular response after discontinuation of imatinib. Additionally, an immunological mechanism modified by interferon-α might control chronic myeloid leukemia stem cells.

KW - Chronic myeloid leukemia

KW - Discontinuation

KW - Imatinib

KW - Molecular recurrence

UR - http://www.scopus.com/inward/record.url?scp=84862136806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862136806&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.056853

DO - 10.3324/haematol.2011.056853

M3 - Article

C2 - 22180435

AN - SCOPUS:84862136806

VL - 97

SP - 903

EP - 906

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -